Dissolution Testing for Supplement Tablets and Capsules: The Bioavailability Test Most Brands Never Order

A 500 mg magnesium glycinate tablet can pass every identity and potency check on its COA — 98% label claim accuracy, no heavy metals, no microbial failures — and still deliver essentially nothing to the person who swallowed it. That’s not hypothetical. It’s the practical reality of dissolution failure, and it’s something we flag more often than most brands expect when we run USP <711> testing on commercially available supplement tablets and capsules.

Most supplement brands focus their third-party testing on what’s in the product. Dissolution testing asks a fundamentally different question: does what’s in the product actually come out?

What USP <711> Measures — and Why It’s Not the Same as Disintegration

“Disintegration” and “dissolution” get used interchangeably in conversations with supplement manufacturers. That’s a mistake that leads to real testing gaps.

Disintegration testing (USP <701>) measures how long a solid dosage form takes to break apart into granules. A tablet that disintegrates in 30 minutes has done exactly one thing: fallen apart. The active ingredient particles are still embedded in a carrier matrix, surrounded by excipients, and nowhere near being absorbed.

Dissolution testing — governed by USP General Chapter <711> for pharmaceutical products and USP <2040> specifically for dietary supplements — measures how much of the active ingredient actually moves from that solid matrix into solution under conditions designed to mimic GI physiology. That’s the step that determines bioavailability.

USP <711> defines two primary apparatus types. Apparatus 1 uses a rotating basket immersed in a dissolution vessel; Apparatus 2 uses a paddle. The choice between them depends on the dosage form — tablets typically run on Apparatus 2, capsules on Apparatus 1 — and method development matters enormously. An inappropriate apparatus or the wrong paddle speed (50 rpm vs. 75 rpm changes results more than most formulators realize) can produce passing data that masks real-world release problems.

The dissolution medium matters just as much. Most immediate-release supplements are tested in 900 mL of 0.1N hydrochloric acid (simulating gastric fluid at pH ~1.2) or a phosphate buffer at pH 6.8 (simulating intestinal fluid). Some nutrients — particularly iron, calcium, and zinc — have pH-dependent solubility profiles that make medium selection critical. A calcium carbonate tablet dissolves readily in acid but can lock up at neutral pH. If your dissolution method doesn’t account for that chemistry, you’ll generate a passing result that doesn’t reflect what happens above the pylorus.

Why Most Supplement Brands Skip This Test — and Why That’s Changing

FDA’s current Good Manufacturing Practice regulations at 21 CFR Part 111 don’t explicitly require dissolution testing for dietary supplement tablets. The regulations require you to verify identity, purity, strength, and composition — but give manufacturers latitude in how those tests are designed. In practice, most brands interpret that latitude to mean: run a potency assay, confirm label claim, and ship.

That interpretation is defensible from a strict compliance standpoint. But it sidesteps what USP Chapter <2040> — published specifically for dietary supplements — actually signals. USP guidance for supplement tablets says they should meet the same disintegration and dissolution standards as conventional immediate-release pharmaceutical tablets unless the formulation justifies a different standard. For uncoated immediate-release tablets, that generally means not less than 75% of the labeled amount dissolved within 45 minutes under USP conditions. That’s the Q value most labs apply.

We’ve run dissolution testing on tablets from facilities with clean GMP audit histories and ISO-certified COAs. Roughly 1 in 6 formulations from new clients fails the 75% Q value on first pass. The most common causes: over-compressed tablets (punched too hard during manufacturing, which reduces porosity and slows wetting), film coat weights applied too thick, and excipient combinations that swell and gel rather than disintegrate in acidic conditions.

The regulatory environment is tightening here too. FDA has referenced dissolution failures in warning letters issued to both pharmaceutical and supplement manufacturers. And the agency’s increased scrutiny on structure/function claims — particularly those implying enhanced bioavailability — creates additional liability for brands that can’t back up absorption language with method data. The FTC has parallel authority over advertising claims, and “superior absorption” on a product with no dissolution data is exactly the kind of unsupported claim both agencies have targeted.

Dosage Forms That Should Never Skip Dissolution Testing

Not every supplement tablet carries equal dissolution risk. But certain formulations should be treated as high-priority candidates for USP <711> or <2040> testing before and after any formulation change.

Enteric-coated products. Enteric coatings are designed to resist dissolution in gastric acid and release in the intestine. The failure mode runs in both directions. A coating that’s too thin releases prematurely in the stomach, destroying acid-sensitive actives like probiotics, proteolytic enzymes, or omega-3 ethyl esters. A coating that’s too thick may never release at all. Standard dissolution testing for enteric-coated products uses a two-stage method: 2 hours in acid followed by 45 minutes in pH 6.8 phosphate buffer. The acid-stage Q value should be not more than 10% released; the buffer-stage Q value should be not less than 75%. If your manufacturer is applying coating by weight percent rather than testing the actual release profile, those two conditions may not both be met.

Extended-release formulations. These carry a different dissolution profile by design — typically measured at three or four time points over 6 to 12 hours. Extended-release testing is more complex and requires a validated method specific to the formulation. If your contract manufacturer developed the matrix, get the method documentation and qualification data before sending product to a third-party lab. Generic extended-release methods that weren’t developed for your specific formulation will produce data of limited interpretive value.

Mineral tablets at therapeutic doses. Calcium carbonate, ferrous sulfate, zinc picolinate, and magnesium oxide all have well-documented pH-dependent solubility. The mineral form matters enormously. Calcium carbonate at 500 mg per tablet has substantially worse dissolution than calcium citrate at the same dose — a difference that matters far more for the 20–30% of supplement users with reduced gastric acid output (elderly populations, long-term PPI users) than for healthy young adults.

Products making bioavailability claims. If your label or marketing copy uses phrases like “enhanced absorption,” “liposomal delivery,” or “superior bioavailability,” you need dissolution data. That’s a structure/function claim that both FDA and the FTC have authority to challenge, and “we assumed the formulation worked” isn’t a defense when a regulator or class-action plaintiff asks for supporting data.

What a Dissolution Test Report Actually Gives You

A properly executed USP <711> run at an ISO 17025 accredited lab will report the dissolution medium and pH, apparatus type and rotation speed, individual vessel data at each time point across 6 or 12 vessels, calculated percentage of label claim released per interval, and the Q value determination with a pass/fail conclusion.

That data is a decision tool, not just a compliance checkbox. If 4 of 6 vessels pass at 45 minutes but 2 fail, that’s a uniformity signal pointing toward granule mixing inconsistencies or press calibration drift — information your contract manufacturer needs to investigate. If all 6 vessels release 90%+ in 15 minutes on an extended-release formulation, that’s a coating-failure signal that could produce adverse outcomes in consumers relying on the controlled-release profile.

One pattern we observe consistently: brands that run dissolution testing early in formulation development — before locking the commercial specification — find it far cheaper than brands that run it after launch, when a retailer flags efficacy complaints or Amazon pulls the listing. A single six-vessel dissolution run costs a fraction of what a reformulation, relabeling, and inventory recall event costs. And unlike many quality testing investments, the data you generate carries forward into your technical file and regulatory correspondence.

The 75% Q Value Isn’t a High Bar. But It’s Not a Given Either.

Potency testing tells you what’s on the label. Dissolution testing tells you what the body actually gets. For solid dosage forms, that gap can be significant — and for certain populations and formulations, it’s the difference between a product that performs and one that passes QC but fails the consumer.

If you’re launching a new tablet or capsule formulation, scaling up production, switching contract manufacturers, adding or modifying a coating process, or making any claim related to absorption or bioavailability, dissolution testing belongs in your testing plan. The USP framework already defines the methods and acceptance criteria. The question is whether you’re generating that data before the product ships — or after it doesn’t work the way you promised.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Understanding FDA Software Validation for Supplement Quality Systems — Aurora TIC covers regulatory consulting and 21 CFR compliance frameworks that complement your lab testing documentation strategy.
• Supplier Qualification and Raw Material COA Verification for Supplement Ingredients — Ayah Labs specializes in raw material testing and upstream supplier qualification to catch formulation quality issues before they reach the tablet press.